Drug Topics - January 2009 - (Page 42) Product Updates WHAT’S NEW ment of attention deficit/hyperactivity disorder (ADHD). The 30-minute onset of action can help children with ADHD improve their morning academic productivity in school, says the company. For more information, visit www. focalinxr.com. RX & OTC New Products 1 3 RX CARE New drugs Allergan Inc. has announced the nationwide availability of Aczone (dapsone) Gel 5 percent [1], a new, first-inclass topical treatment for inflammatory acne. Aczone Gel’s topical formulation offers patients a convenient therapy that has proved effective. For more information, visit www.allergan.com. The FDA has approved tapentadol hydrochloride, an immediate-release oral tablet, for the relief of moderateto-severe acute pain. A centrally acting synthetic analgesic with both opioid and non-opioid properties, tapentadol is available in doses of 50 mg, 75 mg, or 100 mg. Tapentadol is manufactured by Janssen Ortho LLC. For more information call (787) 789-5000. Pfizer has announced the FDA has approved the anti-muscarinic agent Toviaz (fesoterodine fumarate) in extended-release tablets for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Toviaz is structurally related to Pfizer’s OAB medication Detrol LA (tolterodine tartrate extended-release capsules). The 4 mg and 8 mg doses of Toviaz allow dosing flexibility to optimize treatment based on individual patient response 2 and tolerability. For more information, visit www.toviaz.com. New indication OTC Premarin (conjugated estrogens) Vagi- Biocodex Inc., is offering Florastor [2], nal Cream 0.5 g has been approved a probiotic treatment, in new 20-count by the FDA for a new indication and blister packs designed to make treata less-frequent, twice-weekly dosing ment and prevention of antibiotic-asregimen to treat moderate-to-severe sociated diarrhea (AAD) more convepostmenopausal dyspareunia (painful sexual Advertiser Index intercourse). According to the company, a ASTEPRO Meda Pharmaceuticals 29-30 low-volume regimen CANCER CARE Ortho-Biotech 21 of Premarin Vaginal CORICIDIN Schering-Plough HealthCare 13 Cream can treat painCORPORATE Actavis 11 ful intercourse due to CORPORATE Apothecary RX 31 menopause, restore CORPORATE Board of Pharmaceutical Specialties 19 vaginal tissue, and reCORPORATE Mylan Pharmaceuticals 24-25 verse changes in the CORPORATE PRS Pharmacy Services 27 vagina that occur with menopause. Visit www. CORPORATE QS / 1 5 wyeth.com for more inCORPORATE Teamstaff RX CV3 formation. EFFIENT B2B Eli Lilly & Company 9 Novartis has anFENTANYL Teva Pharmaceuticls USA CV2,1,2 nounced that the FLEXPEN Novo Nordisk CV4 FDA has approved a JANUVIA Merck & Company INSERT 30-minute onset of TRILIPIX Abbott Laboratories 7 action for Focalin XR VENLAFAXINE UCB Pharma Inc. 15-17 (dexmethylphenidate ZOSYN Wyeth HSE3-5 HCl) extended-release capsules for the treat- 42 DRUG TOPICS Januar y 2009 COURTESY OF ALLERGAN INC. (1), BIOCODEX, INC. (2), MERCK (3) New generics Sandoz launched the generic version of Inspra (eplerenone) in the United States. Eplerenone is used to treat high blood pressure and heart disease, and will be marketed in 25- and 50-mg strengths. More information is available at www.us.sandoz.com. Sandoz also announced the introduction of sumatriptan injection, a generic equivalent of Imitrex. Sumatriptan is a triptan used to treat migraine headaches and helps to relieve pain and other symptoms, including sensitivity to light and sound, nausea, and vomiting. For information, visit www. us.sandoz.com or call (609) 627-8881. http://www.focalinxr.com http://www.focalinxr.com http://www.us.sandoz.com http://www.us.sandoz.com http://www.toviaz.com http://www.us.sandoz.com http://www.allergan.com http://www.wyeth.com http://www.wyeth.com
Table of Contents Feed for the Digital Edition of Drug Topics - January 2009 Drug Topics - January 2009 Contents Letters Up Front Up Front in Depth Community Practice Drug Pipeline: What to Watch in 2009 OTC Community-Aquired MRSA Infections New Products Viewpoint Drug Topics - January 2009 Drug Topics - January 2009 - Drug Topics - January 2009 (Page Cover1) Drug Topics - January 2009 - Drug Topics - January 2009 (Page Cover2) Drug Topics - January 2009 - Drug Topics - January 2009 (Page 1) Drug Topics - January 2009 - Drug Topics - January 2009 (Page 2) Drug Topics - January 2009 - Drug Topics - January 2009 (Page 3) Drug Topics - January 2009 - Contents (Page 4) Drug Topics - January 2009 - Contents (Page 5) Drug Topics - January 2009 - Contents (Page 6) Drug Topics - January 2009 - Contents (Page 7) Drug Topics - January 2009 - Contents (Page 8) Drug Topics - January 2009 - Contents (Page 9) Drug Topics - January 2009 - Contents (Page 10) Drug Topics - January 2009 - Contents (Page 11) Drug Topics - January 2009 - Letters (Page 12) Drug Topics - January 2009 - Letters (Page H1) Drug Topics - January 2009 - Letters (Page H2) Drug Topics - January 2009 - Letters (Page H3) Drug Topics - January 2009 - Letters (Page H4) Drug Topics - January 2009 - Letters (Page H5) Drug Topics - January 2009 - Letters (Page H6) Drug Topics - January 2009 - Letters (Page H7) Drug Topics - January 2009 - Letters (Page H8) Drug Topics - January 2009 - Letters (Page 13) Drug Topics - January 2009 - Up Front (Page 14) Drug Topics - January 2009 - Up Front (Page 15) Drug Topics - January 2009 - Up Front (Page 16) Drug Topics - January 2009 - Up Front (Page 17) Drug Topics - January 2009 - Up Front in Depth (Page 18) Drug Topics - January 2009 - Up Front in Depth (Page 19) Drug Topics - January 2009 - Community Practice (Page 20) Drug Topics - January 2009 - Community Practice (Page 20a) Drug Topics - January 2009 - Community Practice (Page 20b) Drug Topics - January 2009 - Community Practice (Page 21) Drug Topics - January 2009 - Drug Pipeline: What to Watch in 2009 (Page 22) Drug Topics - January 2009 - Drug Pipeline: What to Watch in 2009 (Page 23) Drug Topics - January 2009 - Drug Pipeline: What to Watch in 2009 (Page 24) Drug Topics - January 2009 - Drug Pipeline: What to Watch in 2009 (Page 25) Drug Topics - January 2009 - Drug Pipeline: What to Watch in 2009 (Page 26) Drug Topics - January 2009 - Drug Pipeline: What to Watch in 2009 (Page 27) Drug Topics - January 2009 - OTC (Page 28) Drug Topics - January 2009 - OTC (Page 29) Drug Topics - January 2009 - OTC (Page 30) Drug Topics - January 2009 - OTC (Page 31) Drug Topics - January 2009 - Community-Aquired MRSA Infections (Page 32) Drug Topics - January 2009 - Community-Aquired MRSA Infections (Page 33) Drug Topics - January 2009 - Community-Aquired MRSA Infections (Page 34) Drug Topics - January 2009 - Community-Aquired MRSA Infections (Page 35) Drug Topics - January 2009 - Community-Aquired MRSA Infections (Page 36) Drug Topics - January 2009 - Community-Aquired MRSA Infections (Page 37) Drug Topics - January 2009 - Community-Aquired MRSA Infections (Page 38) Drug Topics - January 2009 - Community-Aquired MRSA Infections (Page 39) Drug Topics - January 2009 - Community-Aquired MRSA Infections (Page 40) Drug Topics - January 2009 - Community-Aquired MRSA Infections (Page 41) Drug Topics - January 2009 - New Products (Page 42) Drug Topics - January 2009 - New Products (Page 43) Drug Topics - January 2009 - New Products (Page 44) Drug Topics - January 2009 - New Products (Page 45) Drug Topics - January 2009 - New Products (Page 46) Drug Topics - January 2009 - New Products (Page 47) Drug Topics - January 2009 - Viewpoint (Page 48) Drug Topics - January 2009 - Viewpoint (Page Cover3) Drug Topics - January 2009 - Viewpoint (Page Cover4)
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.